Kyntra Bio Inc (KYNB) — Titan Protect Analysis

KYNB

Kyntra Bio Inc

Healthcare · ·

$6.71

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$28M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-0.70

Based on estimated future earnings — lower means cheaper

Rev Growth

+36.5%

Year-over-year revenue change

Profit Margin

2,199.4%

How much profit the company keeps from each dollar of revenue

ROE

N/A

Return on equity — how efficiently it uses shareholder money

Analyst Target

$43.00

+541% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 1 analysts covering this stock

About Kyntra Bio Inc

Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment

https://www.kyntrabio.com

Country: United States Employees: 34 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

-0.256

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0462

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.631

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-52.8%

Historical annualised return based on price data

Max Drawdown

-83.6%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$12.60

47% below the year high

52W Low

$4.85

38% above the year low

Avg Volume

17,753

Average daily shares traded — higher means easier to buy and sell

Short Ratio

14.7

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-13.99

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

-275.4%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-369.1%

Profit from core operations before interest and tax

Free Cash Flow

N/A

Negative — the business is spending more than it generates

Revenue (TTM)

$7M

Total revenue over the last 12 months

Net Income

$-56,570,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$43.00

Target Median

$43.00

Target Low

$43.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go